Ted received a PhD from the University of Minnesota and did postdoctoral research at the University of Virginia.   He was chairman of the research committee and a member of the board of directors of the New Jersey chapter of the American Heart Association. Ted also served on the scientific advisory boards of Sirtris Pharmaceuticals and Syndexa Pharmaceuticals.

From 1979-1998 he was employed at Schering Plough Research Institute and held positions of increasing responsibility in drug discovery and development and was appointed to the position of senior director and Presidential Fellow from 1995-1998. His research efforts contributed to the discovery of new therapies for treating cardiovascular diseases including ezetimibe, a novel and important therapy for treating hypercholesterolemia and vorapaxar, a new antithrombotic agent recently approved by the FDA. Dr. Sybertz joined GelTex Pharmaceuticals in 1998 as senior vice president of Research and Development. In 2000, GelTex merged with Genzyme Corporation.  Ted served as senior vice president and general manager of Drug Discovery and Development at Genzyme until 2011. Ted now serves on the scientific advisory board of Lysosomal Therapeutics and consults with numerous biopharma companies and investors. He is a member of the American Society for Pharmacology and Therapeutics.